SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CNSY

Cerenome, Inc. (NASDAQ:CNSY)

US · Delayed Price · Currency is USD
Also listed: PSTVHealthcare · Medical - Pharmaceuticals
$0.63-$0.07 (-10.29%)
 
Market cap
$6.16M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 3, 2026
Market Cap$6.16M-84.4%
Revenue (ttm)$3.53M-32.9%
Net Income-$30.32M-47.4%
EPS-$4.57+100.0%
Shares Out9.78M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume256,654
Open$0.70
Previous Close$0.70
Day's Range$0.63 - $0.74
52-Week Range$0.43 - $19.00
Beta1.49
AnalystsBuy
Price Targetn/a
Earnings DateMar 11, 2027

About CNSY

Cerenome, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Address
6420 Levit Green Blvd, Houston, TX, 77021, US
Market Cap
6 million
Employees
28
Industrial Classification
Medical - Pharmaceuticals

Analyst consensus

Moderate Buy
2 Buy0 Hold0 Sell

2 firms rating CNSY in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Distressed
From CNSY’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-10.29%
5 Days
-35.34%
1 Month
-63.99%
6 Months
-84.44%
1 Year
-84.44%

$CNSY stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CNSY holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CNSY's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CNSY Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CNSY Revenue by Segment

$2.17MTotal
Personnel costs (including stock-based compensation)$1.45M66.80%
Revenue, net$722.00K33.20%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CNSY patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CNSY from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CNSY

VTIVanguard Morningstar Total Stock Market ETF$292.71K
VXFVanguard Extended Market ETF$146.62K
IWCiShares Micro-Cap ETF$16.07K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CNSY’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
72

News check: Positive interim trial data for REYOBIQ, CNSide diagnostic revenue debut, and commercial progress offset by Q3 net loss but revenue beat estimates.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.